Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
tablet
suspension extended-release tablet |
| gptkbp:brand |
gptkb:Carbatrol
gptkb:Equetro Tegretol |
| gptkbp:chemicalFormula |
CYP3A4
C15H12N2O |
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:commonName |
400-1200 mg/day
|
| gptkbp:contraindication |
gptkb:stevens-johnson_syndrome
gptkb:MAO_inhibitors liver toxicity aplastic anemia toxic epidermal necrolysis hypersensitivity to carbamazepine hyponatremia bone_marrow_suppression |
| gptkbp:endOfLife |
12-17 hours
|
| gptkbp:formulation |
extended-release
immediate-release |
| gptkbp:gestationPeriod |
D
moderate |
| https://www.w3.org/2000/01/rdf-schema#label |
carbamazepine
|
| gptkbp:impact |
long-term
|
| gptkbp:interactsWith |
oral contraceptives
warfarin other anticonvulsants |
| gptkbp:is_monitored_by |
CBC
liver function tests renal function tests |
| gptkbp:isATypeOf |
298-46-4
|
| gptkbp:locatedIn |
1960s
|
| gptkbp:notableFeature |
gptkb:Tegretol_XR
Tegretol Chewable Tegretol Tablets |
| gptkbp:operates_in |
N03AF01
|
| gptkbp:patentMaintenanceFee |
1974
|
| gptkbp:religion |
develops over time
|
| gptkbp:route |
oral
intravenous |
| gptkbp:sideEffect |
dizziness
nausea drowsiness blurred vision |
| gptkbp:symptoms |
anxiety
seizures insomnia |
| gptkbp:triggerType |
sodium channel blocker
|
| gptkbp:usedFor |
treating epilepsy
treating bipolar disorder treating trigeminal neuralgia |
| gptkbp:waterManagement |
urine
feces |